 <h1>Egrifta Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>tesamorelin</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about tesamorelin. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Egrifta.</p><h2>In Summary</h2><p><b>Common side effects of Egrifta include:</b> injection site reaction, erythema at injection site, bruising at injection site, irritation at injection site, and pain at injection site. <b>Other side effects include:</b> limb pain, myalgia, peripheral edema, and decreased glucose tolerance.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to tesamorelin: subcutaneous powder for solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, tesamorelin (the active ingredient contained in Egrifta) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking tesamorelin:</p><p>
<i>More common</i>
</p><ul>
<li>Difficulty with moving</li>
<li>muscle pain or stiffness</li>
<li>pain in the arms or legs</li>
<li>pain in the joints</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Blurred vision</li>
<li>burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings</li>
<li>burning, numbness, pain, or tingling in all fingers except the smallest finger</li>
<li>chest pain</li>
<li>dizziness</li>
<li>fast, irregular, pounding, or racing heartbeat or pulse</li>
<li>headache</li>
<li>nervousness</li>
<li>pounding in the ears</li>
<li>slow or fast heartbeat</li>
<li>swelling of the joints</li>
<li>unsteadiness or awkwardness</li>
<li>weakness in the arms, hands, legs, or feet</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of tesamorelin may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at injection site</li>
<li>muscle aching or cramping</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Acid or sour stomach</li>
<li>belching</li>
<li>bone pain</li>
<li>discouragement</li>
<li>feeling of warmth</li>
<li>feeling sad or empty</li>
<li>heartburn</li>
<li>indigestion</li>
<li>irritability</li>
<li>itching skin</li>
<li>lack of appetite</li>
<li>loss of interest or pleasure</li>
<li>muscle spasms</li>
<li>nausea</li>
<li>night sweats</li>
<li>rash</li>
<li>redness of the face, neck, arms, and occasionally, upper chest</li>
<li>sleeplessness</li>
<li>stiffness of the joints</li>
<li>stomach discomfort, upset, or pain</li>
<li>strain in the muscles</li>
<li>sudden sweating</li>
<li>tiredness</li>
<li>trouble concentrating</li>
<li>trouble sleeping</li>
<li>unable to sleep</li>
<li>upper abdominal or stomach pain</li>
<li>vomiting</li>
</ul><p>
<!-- end subcutaneous powder for solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to tesamorelin: subcutaneous powder for injection</i></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (13.3%)</p>
<p><b>Common</b> (1% to 10%): Pain in extremity, myalgia, musculoskeletal pain, musculoskeletal stiffness, joint stiffness, muscle spasms, joint swelling, muscle strain<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Injection site erythema, injection site pruritus, injection site pain, injection site irritation, injection site hemorrhage, injection site urticaria, injection site swelling, injection site reaction, injection site rash<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Paresthesia, hypoesthesia, carpal tunnel syndrome, peripheral neuropathy<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea, vomiting, dyspepsia, abdominal pain upper<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Diabetes</p>
<p><b>Uncommon</b> (0.1% to 1%): Increased HbA1c<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Palpitations, hypertension, hot flush<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression, insomnia<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash, pruritus, night sweats<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Peripheral edema, pain, chest pain, blood creatine phosphokinase increased</p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Anti- tesamorelin (the active ingredient contained in Egrifta) IgG antibodies (49.5%)</p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Egrifta (tesamorelin)." Theratechnologies Inc., Montreal, ON. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about Egrifta (tesamorelin)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>13 Reviews</li>
<li>Drug class: growth hormones</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Egrifta &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Lipodystrophy</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to tesamorelin: subcutaneous powder for injection</i></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (13.3%)</p><p><b>Common</b> (1% to 10%): Pain in extremity, myalgia, musculoskeletal pain, musculoskeletal stiffness, joint stiffness, muscle spasms, joint swelling, muscle strain<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Injection site erythema, injection site pruritus, injection site pain, injection site irritation, injection site hemorrhage, injection site urticaria, injection site swelling, injection site reaction, injection site rash<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Paresthesia, hypoesthesia, carpal tunnel syndrome, peripheral neuropathy<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea, vomiting, dyspepsia, abdominal pain upper<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Diabetes</p><p><b>Uncommon</b> (0.1% to 1%): Increased HbA1c<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Palpitations, hypertension, hot flush<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression, insomnia<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash, pruritus, night sweats<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Peripheral edema, pain, chest pain, blood creatine phosphokinase increased</p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Anti- tesamorelin (the active ingredient contained in Egrifta) IgG antibodies (49.5%)</p><p id="ref_1">1. "Product Information. Egrifta (tesamorelin)." Theratechnologies Inc., Montreal, ON. </p><h2>More about Egrifta (tesamorelin)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>13 Reviews</li>
<li>Drug class: growth hormones</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Egrifta &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Lipodystrophy</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>